{
    "eid": "2-s2.0-85152274374",
    "title": "Glioblastoma with novel EGFR mutations (T790M and exon 20 insertion) yet unresponsive to osimertinib: A case report",
    "cover-date": "2023-07-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Genetics",
            "@code": "1311",
            "@abbrev": "BIOC"
        },
        {
            "@_fa": "true",
            "$": "Cancer Research",
            "@code": "1306",
            "@abbrev": "BIOC"
        }
    ],
    "keywords": [
        "comprehensive genomic profiling",
        "EGFR",
        "exon 20 insertion",
        "glioblastoma",
        "next-generation sequencing",
        "osimertinib",
        "T790M",
        "tyrosine kinase inhibitor"
    ],
    "authors": [
        "Atthaporn Boongird",
        "Nopphon Lekcharoensombat",
        "Artit Jinawath",
        "Talent Theparee",
        "Nutchawan Jittapiromsak",
        "Shanop Shuangshoti",
        "Paul Scott Thorner",
        "Chinachote Teerapakpinyo"
    ],
    "citedby-count": 1,
    "ref-count": 45,
    "ref-list": [
        "Personalized medicine in the oncology clinic: implementation and outcomes of the Johns Hopkins molecular tumor board",
        "Classification, ontology, and precision medicine",
        "Comprehensive genomic profiling for patients with chemotherapy-naive advanced cancer",
        "Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial",
        "Clinical sequencing using a next-generation sequencing-based multiplex gene assay in patients with advanced solid tumors",
        "Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: a hospital-based study",
        "EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer",
        "Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer",
        "Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer",
        "The 2021 WHO classification of tumors of the central nervous system: a summary",
        "CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014",
        "EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood",
        "Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies",
        "The somatic genomic landscape of glioblastoma",
        "Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation",
        "EGFR exon 20 insertion in bithalamic and unithalamic glioma: a report of 2 cases and literature review",
        "Prospective, high-throughput molecular profiling of human gliomas",
        "Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas",
        "Epidermal growth factor receptor variant III (EGFRvIII) positivity in EGFR-amplified glioblastomas: prognostic role and comparison between primary and recurrent tumors",
        "Genetic alterations in primary glioblastomas in Japan",
        "Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain",
        "Spatiotemporal genomic architecture informs precision oncology in glioblastoma",
        "BRAF mutations may identify a clinically distinct subset of glioblastoma",
        "The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone",
        "Novel MSH6 mutations in treatment-naive glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation",
        "Treatment-associated TP53 DNA-binding domain missense mutations in the pathogenesis of secondary gliosarcoma",
        "Loss-of-function mutations in calcitonin receptor (CALCR) identify highly aggressive glioblastoma with poor outcome",
        "Gene mutation profiling of primary glioblastoma through multiple tumor biopsy guided by 1H-magnetic resonance spectroscopy",
        "Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients",
        "Gene dosage and mutational analyses of EGFR in oligodendrogliomas",
        "Next generation DNA sequencing of atypical choroid plexus papilloma of brain: identification of novel mutations in a female patient by ion proton",
        "Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients",
        "Antitumor activity of osimertinib, an irreversible mutant-selective EGFR tyrosine kinase inhibitor, in NSCLC harboring EGFR exon 20 insertions",
        "Mechanisms of EGFR resistance in glioblastoma",
        "CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials",
        "High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: results from the phase 2 multicenter POSITION20 trial",
        "A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer",
        "Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer",
        "Poziotinib in non-small-cell lung cancer harboring HER2 exon 20 insertion mutations after prior therapies: ZENITH20-2 trial",
        "Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition",
        "Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma",
        "Use of gefitinib in EGFR-amplified refractory solid tumors: An open-label, single-arm, single-center prospective pilot study",
        "Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification",
        "Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors",
        "Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib\u2014a phase II trial"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60199578",
            "affilname": "Ramathibodi Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199578",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Toronto",
            "@id": "60016849",
            "affilname": "University of Toronto",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016849",
            "affiliation-country": "Canada"
        }
    ],
    "funding": [
        "Chulalongkorn University"
    ]
}